161 related articles for article (PubMed ID: 36696853)
1. Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting.
Andrif M; Elmarrachi H; Ismaili N
Cancer Treat Res Commun; 2023; 35():100677. PubMed ID: 36696853
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
3. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC
J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714
[TBL] [Abstract][Full Text] [Related]
4. Highlights in breast cancer from ASCO 2016.
Cardoso F
ESMO Open; 2016; 1(5):e000106. PubMed ID: 27900208
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
6. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease.
Chia SK
Am Soc Clin Oncol Educ Book; 2015; ():e41-8. PubMed ID: 25993203
[TBL] [Abstract][Full Text] [Related]
9. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
10. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
Zhou Q; Yin W; Du Y; Lu J
PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
[TBL] [Abstract][Full Text] [Related]
11. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
12. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
Denduluri N; Somerfield MR; Chavez-MacGregor M; Comander AH; Dayao Z; Eisen A; Freedman RA; Gopalakrishnan R; Graff SL; Hassett MJ; King TA; Lyman GH; Maupin GR; Nunes R; Perkins CL; Telli ML; Trudeau ME; Wolff AC; Giordano SH
J Clin Oncol; 2021 Feb; 39(6):685-693. PubMed ID: 33079579
[TBL] [Abstract][Full Text] [Related]
13. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Perez EA; Dueck AC; McCullough AE; Reinholz MM; Tenner KS; Davidson NE; Gralow J; Harris LN; Kutteh LA; Hillman DW; Jenkins RB; Chen B
J Natl Cancer Inst; 2012 Jan; 104(2):159-62. PubMed ID: 22138096
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
[TBL] [Abstract][Full Text] [Related]
16. ASCO 2020: highlights in breast cancer.
Bartsch R
Memo; 2021; 14(1):58-61. PubMed ID: 33520003
[TBL] [Abstract][Full Text] [Related]
17. American Society of Clinical Oncology (ASCO) - 55th Annual Meeting (May 31-June 4, 2019 - Chicago, Illinois, USA).
Kibble A; Kuenneman K; de Las Heras Prat P
Drugs Today (Barc); 2019 Jun; 55(6):407-415. PubMed ID: 31250844
[TBL] [Abstract][Full Text] [Related]
18. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
20. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
